ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2754

Predictors of Quality of Life in Behçet’s Syndrome

Selma Bozcan1, Yesim Ozguler1, Koray Tascilar1, Caner Saygin1, Didem Uzunaslan1 and Gulen Hatemi2, 1University of Istanbul, Cerrahpasa Medical Faculty, Rheumatology, Istanbul, Turkey, 2Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Behcet's syndrome and quality of life

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Vasculitis

Session Type: Abstract Submissions (ACR)

Background/Purpose: Quality of life is commonly impaired in patients with chronic inflammatory diseases. The disease itself as well as the drugs used may be responsible for this impairment. Behçet’s syndrome (BS) is a multisystem vasculitis with a wide variety of manifestations including oral ulcers, genital ulcers, nodular lesions, papulopustular lesions, arthritis, uveitis, venous thrombosis, arterial aneurysms, neurologic and gastrointestinal involvement. Determining the factors affecting quality of life in BS patients, would help developing effective management strategies.

Methods: Behçet Disease Quality of Life (BDQoL) and Short- Form 36 (SF-36) questionnaires were filled by consecutive BS patients attending our outpatient clinic. Socioeconomic factors, each type of organ involvement during the disease course, during the previous 4 weeks, disabilities caused by each, treatment modalities and overall disease activity were tested with regression analysis as possible determinants of quality of life.  Men and women were also analyzed separately.

Results: 322 patients (M/F: 166/156, mean age: 37.9±11.1 years) were included. 157 patients had eye involvement, 72 patients had vascular involvement, 67 patients had joint involvement, 20 patients had neurologic involvement, 2 patients had gastrointestinal involvement and 93 patients had only mucocutaneous involvement without major organ involvement.  Determinants of BDQoL in the whole group were BSAS, household income, work disability, perception of insufficient income, neurologic damage (R²:0.47, F: 48.76, p<0.001). Among women they were BSAS, perception of insufficient income, neurologic and mucocutaneous involvement (R²:0.40, F: 19.75, p<0.001). Among men they were work disability, BSAS, household income, perception of insufficient income, vascular involvement during the last 4 week and damage caused by neurologic involvement (R²:0.56, F: 29.70, p<0.001). SF-36 scores were well correlated with BDQoL scores (r=-0.69 for physical component and r=-0.63 for mental component). 

Conclusion: In addition to overall disease activity and neurologic damage, mucocutaneous involvement in women and recent eye and vascular events in men seem to impair quality of life in BS. These findings are important for developing management strategies and outcome measures.

 


Disclosure:

S. Bozcan,
None;

Y. Ozguler,
None;

K. Tascilar,
None;

C. Saygin,
None;

D. Uzunaslan,
None;

G. Hatemi,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/predictors-of-quality-of-life-in-behcets-syndrome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology